Nutriband Inc. (NTRB)
NASDAQ: NTRB · Real-Time Price · USD
7.30
+0.13 (1.81%)
At close: Sep 26, 2025, 4:00 PM EDT
7.36
+0.06 (0.82%)
After-hours: Sep 26, 2025, 4:14 PM EDT
Nutriband Employees
Nutriband had 13 employees as of January 31, 2022. The number of employees increased by 8 or 160.00% compared to the previous year.
Employees
13
Change (1Y)
8
Growth (1Y)
160.00%
Revenue / Employee
$198,312
Profits / Employee
-$2,467,881
Market Cap
87.24M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jan 31, 2022 | 13 | 8 | 160.00% |
| Jan 31, 2021 | 5 | 2 | 66.67% |
| Jan 31, 2020 | 3 | -4 | -57.14% |
| Jan 31, 2019 | 7 | -3 | -30.00% |
| Jan 31, 2018 | 10 | 8 | 400.00% |
| Jan 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NTRB News
- 2 days ago - Nutriband Inc. to Present at the MicroCap Rodeo Conference - GlobeNewsWire
- 17 days ago - Nutriband Inc. Quarterly Report Highlights Record Revenue for Q2, 2025 up 50.87% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl - GlobeNewsWire
- 23 days ago - Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $5,306,000 - GlobeNewsWire
- 5 weeks ago - Nutriband Inc. to Present on the Emerging Growth Conference on August 20, 2025 - GlobeNewsWire
- 6 weeks ago - Nutriband CEO Gareth Sheridan Seeks Nomination in Upcoming Irish Presidential Election - GlobeNewsWire
- 7 weeks ago - FDA Grants Nutriband Meeting Request for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch - GlobeNewsWire
- 2 months ago - Nutriband Confirms Record and Pay date for 25% Preferred Stock Dividend as it Targets Filing for FDA Approval - GlobeNewsWire
- 3 months ago - Nutriband Announces 25% Preferred Stock Dividend as it targets filing for FDA approval - GlobeNewsWire